Olaparib approved in the EU for use in combination with bevacizumab as first-line maintenance treatment for homologous recombination deficiency (HRD)-positive advanced ovarian cancer

The approval of olaparib in this setting was based on a biomarker subgroup analysis of the PAOLA-1 Phase III trial, which showed that its use in combination with bevacizumab was associated with longer progression-free survival than bevacizumab alone.

Biospace Inc.